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Abstract
Background: The onset of acute Graft-versus-Host Disease (aGvHD) has been correlated with the gut microbiota
(GM) composition, but experimental observations are still few, mainly involving cohorts of adult patients. In the
current scenario where fecal microbiota transplantation has been used as a pioneer therapeutic approach to treat
steroid-refractory aGvHD, there is an urgent need to expand existing observational studies of the GM dynamics in
Hematopoietic Stem Cell Transplantation (HSCT). Aim of the present study is to explore the GM trajectory in 36
pediatric HSCT recipients in relation to aGvHD onset.
Methods: Thirty-six pediatric patients, from four transplantation centers, undergoing HSCT were enrolled in the
study. Stools were collected at three time points: before HSCT, at time of engraftment and > 30 days following HSCT.
Changes in the GM phylogenetic structure were studied by 16S rRNA gene Illumina sequencing and phylogenetic
assignation.
Results: Children developing gut aGvHD had a dysbiotic GM layout before HSCT occurred. This putative aGvHD-
predisposing ecosystem state was characterized by (i) reduced diversity, (ii) lower Blautia content, (iii) increase in
Fusobacterium abundance. At time of engraftment, the GM structure underwent a deep rearrangement in all
patients but, regardless of the occurrence of aGvHD and its treatment, it reacquired a eubiotic configuration
from day 30.
Conclusions: We found a specific GM signature before HSCT predictive of subsequent gut aGvHD occurrence.
Our data may open the way to a GM-based stratification of the risk of developing aGvHD in children undergoing HSCT,
potentially useful also to identify patients benefiting from prophylactic fecal transplantation.
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Background
Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT) is a curative option for many patients with
high-risk hematopoietic malignancies and hematological
disorders. The success of the procedure can be hampered
by a process in which donor-derived T cells recognize host
healthy tissue as non-self, causing an immune-mediated
complication known as acute Graft-versus-Host Disease
(aGvHD), instrumental in determining morbidity and
mortality of the patients.
A relationship between aGvHD and the gut microbiota
(GM) has long been hypothesized, [1–3] because of the
ever-increasing evidence of the involvement of the GM
in the regulation of the human immune system func-
tionality [4, 5]. Few studies, mostly performed in small
cohorts, have documented that aGvHD is associated
with detectable shifts in the composition of the GM, in
both murine and human (adult and child) HSCT recipi-
ents [6–8]. This finding supports the hypothesis that
GM-derived metabolites (e.g. short-chain fatty acids
(SCFAs)) and/or signaling molecules (e.g. microbe-asso-
ciated molecular patterns (MAMPs)) can influence the
onset of aGvHD. Indeed, it has been demonstrated in a
mouse model that bacteria-originated butyrate improves
the junctional integrity of intestinal epithelial cells, de-
creases apoptosis and mitigates aGvHD severity [9].
Some of the studies characterizing the GM dynamics in
HSCT showed that a specific gut microbial population,
the so-called “anti-inflammatory Clostridia”, i.e. mem-
bers of the families Clostridiaceae, Lachnospiraceae,
Ruminococcaceae and Eubacteriaceae, might be involved
in the mechanism by which gut microbes exert a coun-
teracting effect on aGvHD onset and progression [8–10].
A partial confirmation of this observation has been pro-
vided by a study on a larger cohort of adults, in which
the relative abundance of the Lachnospiraceae genus
Blautia was correlated with reduced mortality from
aGvHD [11].
The understanding of the relationship existing be-
tween GM and development of aGvHD is still far from
complete, mostly because of the cumbersome nature of
studies on diseased human subjects. In addition to the
difficulty of enrolling patients for observational trials,
studies on the GM of HSCT recipients can be biased by
many confounding variables, i.e. antibiotic treatment,
proton-pomp inhibitors, chemotherapy protocols,
underlying malignancy, and hospitalization itself. Still,
the need to thoroughly explore this relationship is more
compelling than ever, last considering that transplant-
ation of fecal material has been used as a pioneer thera-
peutic strategy to approach treatment-refractory aGvHD
[12]. The aim of the present work is to expand the pilot
study on the GM dynamics previously performed in 10
pediatric HSCT recipients in relation to the development
of aGvHD [7]. In particular, four transplantation centers
across Italy enrolled a total of 36 individuals, with a longi-
tudinal approach to fecal sampling. The analysis, aside
from attempting to detect microbial signatures that might
be related to the aGvHD onset and/or progression, was
aimed at elucidating the extent of the changes occurring
in the GM composition in relation to aGvHD severity.
Methods
Patients Thirty-six patients (20 male and 16 female)
given allo-HSCT in four pediatric centers in Italy
(Bologna, Pavia, Rome and Verona) between 2012 and
2016, were enrolled in a stool collection protocol ap-
proved by the University of Bologna Ethics Committee
(ref. number 19/2013/U/Tess). Written informed con-
sent was obtained, in accordance with the Declaration of
Helsinki, from each enrolled patient or parent/legal
guardian. Inclusion criterion was the availability of a
pre-HSCT fecal sample and of at least two samples col-
lected after HSCT. For one subject, the material col-
lected at time of engraftment was insufficient to extract
good-quality bacterial DNA; therefore, only one
post-HSCT sample was included (Fig. 1). Patients with
either malignant (63% of cases) or non-malignant dis-
eases were included; in particular, eight of 23 patients
with malignant disease were classified as having high-
risk disease. All transplantation procedures took place in
HEPA-filtered single rooms where standard precaution-
ary and hygienic measures were applied. Antibiotic gut
decontamination during the conditioning regimen was
not routinely performed. Only five out of 36 patients re-
ceived intravenous levofloxacin [13] from the beginning
of the conditioning regimen to the complete neutrophil
recovery. All patients observed complete fasting begin-
ning from the onset of oral mucositis or diarrhea with
administration of parenteral nutrition until the day of
engraftment. As for conditioning regimen, 32 patients
received a myeloablative busulfan (or treosulfan)-based
conditioning regimen, three patients received total body
irradiation-based conditioning regimen and one patient
received a non-myeloablative preparative regimen with
cyclophosphamide/fludarabine. Antiviral and antifungal
prophylaxis was administered from day − 1 and + 2 re-
spectively, as recommended [14, 15]. Antibiotic empiric
therapy, with piperacillin/tazobactam or ceftazidime was
given in case of neutropenic fever in 29/36 cases. Seven
cases received antibiotic therapy at the beginning of the
neutropenic phase independently from the onset of
fever, and four cases received a cephazolin/piperacillin
tazobactam-based anti-streptococcal prophylaxis before
the engraftment phase. Two patients developed sepsis,
one sustained by Escherichia coli before graft infusion
and the other by Klebsiella pneumoniae after cells
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infusion and before the neutrophil engraftment. Con-
cerning the types of allograft administered, 29/36 pa-
tients received unmanipulated bone marrow cells, while
6/36 patients received T-cell depleted peripheral blood
stem cells and 1/36 cord blood cells. Neutrophil and
platelet engraftment were defined as occurring on the
first of the three consecutive days on which the neutrophil
count was > 0.5 × 109/L and platelets were > 20 × 109/L,
respectively. Only one patient experienced primary graft
failure.During the procedure, 19 of 36 patients developed
aGvHD; six had gut involvement. All patients with skin
and gastrointestinal aGvHD (grade I-III according to the
Seattle criteria) [16] were treated with steroids, while one
patient with skin grade III aGvHD also received
extracorporeal photopheresis. One patient with severe
gastrointestinal grade IV aGvHD was treated with ste-
roids, extracorporeal photopheresis and infliximab.
Sample collection and bacterial DNA isolation
Stool samples were collected using sterile stool collection
tubes, stored at minimum − 20 °C and shipped in dry ice
to the laboratory where microbiological analyses were
performed. Total bacterial DNA was extracted from
250mg of each sample following a previously described
protocol [17].
16S rRNA gene amplification and sequencing
The V3-V4 region of the 16S rRNA gene was PCR ampli-
fied, using S-D-Bact-0341-b-S-17/S-D-Bact-0785-a-A-21
primers carrying Illumina overhang adapter sequences,
[18] at a final concentration of 200 nmol/L. Twenty-five
ng of microbial DNA were used as a template in a final re-
action volume of 50 μL. KAPA HiFi HotStart ReadyMix
(KAPA Biosystems, Resnova, Italy) was used for the amp-
lification. The thermal cycle was set as follows: 3min at
95 °C, 25 cycles of 30 s at 95 °C, 30 s at 55 °C, and 30 s at
72 °C, and a final 5-min step at 72 °C. Amplicons were
purified with a magnetic bead-based clean-up system
(Agencourt AMPure XP; Beckman Coulter, Brea, CA).
Indexed libraries were prepared by limited-cycle PCR
using Nextera technology, followed by a second AMPure
XP magnetic beads clean-up step. Final libraries were
Fig. 1 Schematic overview of the sampling time for each enrolled subject. Subjects are indicated with a progressive number preceded by a letter
associated with the enrolling center (B, Bologna; P, Pavia; R, Rome; V, Verona). HSCT (green dots), skin grade I-III aGvHD diagnosis (yellow dots),
gastrointestinal grade II-IV aGvHD diagnosis (red dots), and fecal sample collection (black dots) are plotted on timelines with distance from HSCT
expressed in days
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prepared by equimolar (4 nmol/L) pooling, denaturation
and dilution to 6 pmol/L before loading onto the HiSeq
flow cell. A 2 × 250 bp paired-end protocol was used,
according to manufacturer’s instructions (Illumina, San
Diego, CA).
Bioinformatics and statistics
Raw sequences were processed using a pipeline combin-
ing PANDAseq and QIIME [19, 20]. Sequencing reads
were deposited on European Nucleotide Archive (ENA)
(http://www.ebi.ac.uk/ena/data/view/PRJEB23820).
High-quality reads, as selected using the default values
in QIIME, were binned into operational taxonomic units
(OTUs) according to the taxonomic threshold of 97%
using UCLUST, [21] through an open-reference strategy.
For statistical purposes, the OTU tables from subjects
included in the study of Biagi et al. [7] were included in
the analyses, and taxonomy for all samples was assigned
using the RDP classifier against Greengenes database
(May 2013 release). Chimeras and singleton OTUs were
discarded. Statistics was performed using R software
(https://www.r-project.org/) and the libraries vegan,
made4, Random Forest, and rfPermute. Since samples
from Biagi et al. [7] were sequenced with a different
technique (Roche 454 pyrosequencing vs. Illumina) and
using a smaller region of the 16S rRNA gene for assign-
ment (V4 only vs. V3-V4), analyses were performed
using genus-level relative abundances for Principal
Coordinates Analysis (PCoA) based on Bray-Curtis dis-
tances. Datasets were filtered for genera present at rela-
tive abundance > 0.1% in at least one sample. Data
separation in the PCoA was tested using a permutation
test with pseudo F ratios (function adonis in the vegan
package). Bacterial groups with the largest contribution
to the ordination space were found by using the function
envfit of the R package vegan on the genus relative
abundances. The impact of different variables on the
microbiota structure was explored by using the Random
Forest machine learning algorithm [22]. Briefly, Random
Forests is a powerful classifier that identifies the best
subset of features (here, relative abundances at genus
level) to discriminate among categories (age groups,
studies, hospitals, types of hematological disease).
Wilcoxon test was used to assess significant differences
between two groups of samples; adaptations for paired
samples were used when necessary. Kruskal-Wallis test
was used for multiple comparisons, followed by Tukey
post-hoc test when appropriate. All P values were cor-
rected for multiple comparisons using the Benjamini-
Hochberg method (the number of hypotheses tested for
each comparison ranged between 40 and 64). A false dis-
covery rate (FDR) of 5% was used. Finally, sequences
assigned to a selected group of taxa, namely Entero-
coccus, Citrobacter, Erwinia, Fusobacterium, Blautia,
and Bacteroides, were subjected to additional analysis
using the tool Oligotyping [23]. Following the initial en-
tropy analysis, oligotyping was performed using version
2.1 of the Oligotyping pipeline with a total of 5 positions
with high entropy, chosen to compute the oligotypes
(−C option). To minimize the impact of sequencing er-
rors, we imposed that each oligotype must have at least
10 reads belonging to the most abundant unique sequence.
Species-level assignment of the obtained oligotypes was
carried out using BLAST, with the representative sequences
of each oligotype as a query against the whole 16S rRNA
gene sequence NCBI database.
Results
The 16S rRNA gene-based GM phylogenetic compos-
ition was obtained by Illumina sequencing of a total of
78 fecal samples, taken from 26 subjects, enrolled in
four Italian hospitals. A mean of 11,325 ± 4480 high
quality sequences per sample was obtained. Fifty-three
samples from 10 subjects enrolled at the Sant’Orsola-
Malpighi hospital of Bologna, sequenced in our previous
study on the same topic, [7] were also included in the
analysis, obtaining a final cohort of 131 samples from 36
subjects. Clinical and transplant characteristics are sum-
marized in Table 1. Samples were grouped as “pre” (i.e.
samples taken before HSCT), “engraftment” (i.e. the first
sample taken after HSCT for all subjects, corresponding
approximately to the time of hematopoietic engraftment,
ranging from 12 to 28 days after HSCT), and “post” (all
other samples taken after HSCT) (Fig. 1).
Exploration of confounding variables
Principal Coordinates Analysis (PCoA) based on
Bray-Curtis distances between genus-level microbial
profiles showed no separation between the samples se-
quenced in the present work and those from our previ-
ous study [7] (adonis test, P > 0.05) (Additional file 1:
Figure S1). However, according to the Random Forest
analysis, the relative abundance of some bacterial genera
was discriminatory between studies (P < 0.01, error rate
4.6%), namely Streptococcus (average 0.7 and 6.2% in the
2015 study and in the present study, respectively),
Erwinia (0 and 6.8%), [Eubacterium] (6.1 and 0.8%), and
[Ruminococcus] (6.3 and 3.8%). Mentioned taxa were not
excluded from subsequent analysis, but caution was
taken in associating them with other variables, because
of their possible relation to the different sequencing
techniques used in the two studies (Roche 454 pyrose-
quencing of the 16S rRNA gene V4 hypervariable region
in the 2015 study, and Illumina sequencing of the 16S
rRNA gene V3-V4 hypervariable regions in the present
study).
According to the Random Forest analysis, the
genus-level GM profile did not significantly discriminate
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between age groups, i.e. “baby” (< 2 years), “pediatric”
(2–12 years), and “teen” (> 12 years) (error rate, 37%).
PCoA analysis confirmed the overlapping between sam-
ples from pediatric and teen groups, in all considered
group of samples (pre, engraftment and post). However,
a separation of the samples taken from the subjects in
the “baby” group was revealed in pre and post sample
groups (adonis test, P = 0.002 and P = 0.006, respectively)
(Additional file 1: Figure S2). The latter results highlight
the loss, and the subsequent recovery, of age-specific
GM features following HSCT.
Random Forest analysis also confirmed that the hos-
pital where patients were recruited was an important
variable impacting on the genus-level GM profile, with
the Bologna hospital being the more easily discriminated
(error rate, 16%). PCoA analysis confirmed the impact of
the hospitalization center on all considered group of
samples (pre, engraftment and post) (adonis test, P =
0.003, P = 0.001 and P = 0.001, respectively) (Additional
file 1: Figure S3). The relative abundances of Entero-
coccus, Citrobacter, Erwinia, as well as of unclassified
members of Aerococcaceae and Clostridiales, were dis-
criminatory for samples taken in the different hospitals
(P < 0.01). As mentioned above, these taxa were not ex-
cluded from subsequent analysis, but caution was taken
in associating them with other variables because of their
possible link with the different enrollment centers. In-
deed, a detailed analysis (Additional file 1: Figure S4)
showed that OTUs assigned to Enterococcus were more
relatively abundant in the GM of subjects enrolled in the
Pavia, Verona and Rome hospitals, with respect to the
Bologna hospital, especially in samples taken approxi-
mately at engraftment. All oligotypes obtained from the
Enterococcus-assigned OTUs showed equal identity
score to different Enterococcus species (i.e. Enterococcus
hirae, Enterococcus faecium, Enterococcus ratti, Entero-
coccus villorum), as expected based on the very high
similarity among the 16S rRNA gene sequences of the
species belonging to this genus [24]. Samples from
Verona and Rome hospitals also showed the highest
relative abundances of Citrobacter (in particular in sam-
ples taken before transplantation and after engraftment)
and Erwinia OTUs. Both Citrobacter and Erwinia are
members of the Enterobacteriaceae family. Erwinia is
not commonly reported as a component of the human
GM. It is known that 16S rRNA gene sequencing, while
effective for family-level phylogenetic reconstruction,
may underperform for genus-level phylogenetic analysis
in the Enterobacteriaceae, [25] suggesting that the detec-
tion of high percentages of OTUs assigned to these genera
in some samples may indicate hyper-proliferation of an
array of common enteric pathogens. Therefore, oligotyping
analysis was carried out on sequences assigned to these
genera, and representative sequences were re-assigned
Table 1 Anagraphical and clinical information characteristics of
the enrolled patients
Characteristics N (%) aGvHD No aGvHD P
Age (years) ns
Mean 8.4 8.2 9.0
Range 1–21 2–19 1–21
Female Sex 12 33.3 6 6
Disease ns
ALL 14 38.9 7 7
AML 9 25.0 4 5
Thalassemia Major 5 13.9 2 3
SAA 3 8.3 2 1
BDA 3 8.3 2 1
CDA 1 2.8 1 0
ALPS 1 2.8 1 0
Riska ns
High Risk 8 22.2 5 3
Standard Risk 28 77.8 14 14
Graft Source ns
Unmodified BM 29 80.6 16 13
T-cell Depleted PBSC 6 16.7 2 4
Cord Blood 1 2.8 1 0
Matching HLA ns
Matched 26 72.2 14 12
Mismatched 10 27.8 5 5
Conditioning Regimenb ns
Myeloablative 35 88.9 18 16
Nonmyeloablative 1 11.1 1 0
GvHD Prophylaxis ns
αβ T-cell and B-cell depletion 6 16.7 3 3
Calcineurin Inhibitor alone 7 19.4 4 3
CI + ATG +/− MTX 21 58.3 11 10
CI + ATG + Prednisone 1 2.8 1 0
CI + Cyclophosphamide post 1 2.8 0 1
GvHD 19 52.8
Mean Day of Onset
(days from transplantation)
+ 21
I 5 26.3
II 9 47.4
III 3 15.8
IV 2 10.5
Gut Involvement 6 31.6
Abbreviations: ALL Acute Lymphoblastic Leukemia, AML Acute Myeloid
Leukemia, SAA Severe Aplastic Anemia, BDA Blackfan-Diamond Anemia,
CDA Congenital Dyserythropoietic Anemia, ALPS Autoimmune
Lymphoproliferative Syndrome, BM Bone Marrow, PBSC Peripheral Blood
Stem Cells, GvHD Graft-versus-Host Disease, ATG Anti-Thymocyte Globulin,
MTX Methotrexate, ns not significant
aRisk staging: high risk: >1st complete remission (CR) or refractory disease;
standard risk: 1st CR or non-malignant disease
bAs defined by Bacigalupo et al. [50]
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using NCBI 16S rRNA gene sequence database. Oligotypes
obtained from the Citrobacter-assigned OTUs showed the
highest identity score to one of three commonly reported
nosocomial pathogens, i.e. Citrobacter murliniae, Klebsiella
pneumoniae, and Enterobacter cloacae [26–29]. None of
these species was associated with a specific hospital or one
of the three considered time points (pre, engraftment and
post). On the contrary, the majority of oligotypes obtained
from the Erwinia-assigned OTUs showed the highest iden-
tity score to E. cloacae (72% of the sequences), and a
smaller fraction to K. pneumoniae. In particular, in all sam-
ples where a high percentage of Erwinia-assigned OTUs
was detected (> 10% of the whole microbiota, all from
Verona and Rome hospitals), the oligotypes assigned to E.
cloacae were dominant (93% of the sequences on average).
Finally, a possible effect of the underlying disease on
the GM composition prior to HSCT was investigated.
According to our findings, Random Forest analysis did
not discriminate among subjects affected by different
hematological diseases on the basis of the pre-HSCT
GM composition (error rate, 66.7%).
Analysis of microbiota variability before HSCT in relation
to aGvHD development
PCoA analysis based on genus-level relative abundances
showed no separation between samples taken before
HSCT from subjects who subsequently either did or did
not develop aGvHD (adonis test, P > 0.05) (Fig. 2a).
However, pre-HSCT samples from subjects who did not
develop aGvHD tended to show higher relative abun-
dance of OTUs assigned to the genus Blautia (mostly
assigned to the human gut species Blautia wexlerae, ac-
cording to our oligotyping analysis) compared to sub-
jects who developed any grade of aGvHD (median 8.7%
in non-aGvHD, 4.0% in skin grade I-II aGvHD, and 1.4%
in gut grade II-IV aGvHD; Wilcoxon test, P = 0.046)
(Fig. 2c). Conversely, subjects who developed greater se-
verity aGvHD with gastrointestinal involvement showed
significantly higher relative abundance of Fusobacteriu-
m-assigned OTUs with respect to other samples (median
0% in non-aGvHD and skin grade I-II aGvHD, 0.05% in
gut grade II-IV aGvHD; Kruskal-Wallis test, P = 0.01)
(Fig. 2b), as well as higher prevalence, i.e. percentage of
samples in which OTUs assigned to Fusobacterium were
found above the detection limit (19% in non-aGvHD,
14% in skin grade I-II aGvHD, and 83% in gut grade
II-IV aGvHD). Based on oligotyping analysis and subse-
quent matching against the NCBI 16S rRNA gene data-
base, all OTUs assigned to this genus belonged to the
species Fusobacterium nucleatum. Both Fusobacterium
and Blautia positive and negative association with
aGvHD development and localization were confirmed by
Random Forest analysis (P = 0.006 and P = 0.046, re-
spectively). The same analysis allowed identifying a few
highly subdominant genera that were detected, even at
very low relative abundance, exclusively in pre-HSCT
samples of subjects who did not develop aGvHD (i.e.
Leptotrichia and unclassified members of Barnesiella-
ceae, average relative abundance 0.02% in non-aGvHD
only, P = 0.035 and P = 0.042, respectively).
The pre-HSCT GM biodiversity was found lower in
both gut grade II-IV aGvHD (Simpson index, mean ±
SD = 0.70 ± 0.28) and skin grade I-II aGvHD (0.75 ±
0.16) groups of subjects, with respect to subjects who
did not develop aGvHD (0.79 ± 0.16) (Additional file 1:
Figure S5), although this difference was not statistically
significant. As for the inter-individual variability, the di-
versity between pre-HSCT samples, as approximated by
calculation of Bray-Curtis distances, was higher in sub-
jects developing gut aGvHD (Bray-Curtis distances,
mean ± SD = 0.86 ± 0.15) than in both non-aGvHD sub-
jects (0.72 ± 0.15, Wilcoxon test P = 0.001) and subjects
developing lower-severity skin-only aGvHD (0.77 ± 0.15,
P = 0.02) (Additional file 1: Figure S6).
Analysis of microbiota variability at engraftment in relation
to aGvHD development
PCoA analysis based on genus-level relative abundances,
in samples collected at engraftment, showed that sam-
ples from subjects who developed grade II-IV aGvHD
with gastrointestinal involvement tended to separate
from all other samples (adonis test, P = 0.049) (Fig. 3a).
Two gut aGvHD samples from two children enrolled at
the Verona hospital (subject code, V2 and V3, Fig. 1)
were characterized by > 80% of the OTUs assigned to
the genus Erwinia, and re-assigned by oligotyping ana-
lysis and NCBI 16S rRNA gene database to the species
E. cloacae, and they were plotted distant to the others.
However, since OTUs assigned to the genus Erwinia
were among those listed as possibly influenced by both
the sequencing technique and the hospital in which pa-
tients were enrolled (Additional File 1: Figure S4), this
data might be biased and was not further explored.
Engraftment samples of patients with gut grade II-IV
aGvHD tended to show higher relative abundance of
Bacteroides (median 0.7% in non-aGvHD, 0.8% in skin
grade I-II aGvHD, and 23.7% in gut grade II-IV aGvHD;
Kruskal-Wallis test, P = 0.050) (Fig. 3b). According to
our oligotyping analysis, the Bacteroides species compos-
ition showed high variability among individuals, with dif-
ferent proportion of the most common human gut
Bacteroides species, such as Bacteroides ovatus, Bacter-
oides vulgatus, Bacteroides uniformis, and Bacteroides
dorei. We could not observe any association between the
detection of a specific Bacteroides species and the onset
of gut grade II-IV aGvHD.
The comparison of pre-HSCT and engraftment sam-
ples from the same subjects showed that the HSCT
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event resulted in a decrease in the relative abundance of
several genera important for a symbiotic, health-promoting
relationship between GM and host, namely Faecalibacter-
ium, [Ruminococcus], Roseburia, Lachnospira, Dorea,
Coprococcus, Blautia (paired Wilcoxon test, P < 0.05)
(Fig. 3c, d, e). In relation to the subsequent development
of aGvHD, we found that in subjects developing gut grade
II-IV aGvHD (Fig. 3e) the changes occurring after HSCT
were less evident than in all other subjects (Fig. 3c and d)
and not significant, hinting that those well-known
health-promoting bacterial groups were already less
relatively abundant on average before HSCT, even if
the comparison with the other pre-HSCT samples
showed significant differences only for Blautia (Fig. 2c,
Additional file 2: Table S1). This might be related to the
higher pre-HSCT variability found in subjects who devel-
oped gut aGvHD (Additional file 1: Figure S6), which might
have hindered the detection of common dysbiotic features.
Analysis of microbiota variability > 30 days after HSCT
PCoA analysis based on genus-level relative abundances
showed no separation between samples taken > 30 days
after HSCT from subjects who subsequently either did or
did not develop aGvHD (adonis test, P > 0.05) (Additional
file 1: Figure S7). Random Forest analysis confirmed the
absence of significant difference in the post-HSCT GM
profile among patients developing either skin or gut
aGvHD (error rate, 55%).
Discussion
The study presented here is a multicenter, longitudinal
observation of microbiota dynamics in pediatric patients
undergoing HSCT for a variety of hematological dis-
eases. The pediatric cohort also included children aged
2 years or less, whose intestinal ecosystem is known to
be highly dynamic in its progressive “maturation” toward
the typically adult GM structure [30, 31]. As a confirm-
ation of the peculiarity of this phase of life for the GM
assembly, in our study, samples from 2-year-old or
younger patients were found to significantly separate
from all other samples, both before HSCT and 1 month
after the procedure. Interestingly, this was not true for
the samples taken at engraftment, highlighting the ex-
tensiveness of the perturbation induced on the GM
Fig. 2 Gut microbiota variability before HSCT, in relation to aGvHD development. a PCoA based on Bray-Curtis distances of genus-level relative
abundance profiles of samples collected before HSCT from patients who did not develop aGvHD (green), who developed aGvHD (I-II grade) only
involving the skin (gold), and who developed gastrointestinal aGvHD (II-IV grade) (dark red). Samples are identified by filled circles. First and
second principal components (MDS1 and MDS2) are plotted, accounting for 22.1 and 13.3% of variance in the dataset, respectively. Box
and whiskers distribution of the relative abundance (%) of OTUs assigned to the genera Fusobacterium (b) and Blautia (c) in samples collected
before HSCT from subjects who did not develop aGvHD (green), who developed aGvHD (I-II grade) only involving the skin (gold), and who developed
gastrointestinal aGvHD (II-IV grade) (dark red)
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structure by HSCT that temporarily cancels the
age-dependent signature in the intestinal microbial
composition.
When we explored the impact of different hospitals in
which patients were treated, the relative abundance of
few genera was found discriminating for the enrollment
center, and this was taken into account in interpreting
the results of the subsequent analysis and evaluating
their significance. The detected discriminant genera (e.g.
Enterococcus, Citrobacter, and other members of Entero-
bacteriaceae, such as Enterobacter and Klebsiella) are
opportunistic members of the human GM, whose pres-
ence could possibly be related to the hospital environ-
ment itself. Indeed, Citrobacter, Enterococcus, Klebsiella
and Enterobacter are well-known possible sources of
nosocomial bloodstream infections that are an important
cause of morbidity and mortality in children undergoing
HSCT [26–29, 32]. Patient’s colonization and hospital
dissemination of potentially multidrug-resistant bacteria are
considered a worrisome phenomenon in hematological pa-
tients [33]. Considering that Enterobacteriaceae are known
for their potential for rapid dissemination in healthcare
settings and because they can cause severe infections,
inter-hospital GM differences should be checked for in all
future multi-center studies and taken into account in rou-
tine clinical practice and patient management [29]. Never-
theless, the relative abundance of these genera was not
found significantly associated with the subsequent develop-
ment of aGvHD, so these center-related variations should
not have biased the results of our study.
Despite the complexity of this study in terms of pos-
sible confounding variables (i.e. chemotherapy, antibi-
otics, proton-pump inhibitors, and hospitalization), it
was possible to detect a signature of the future develop-
ment of aGvHD in the GM composition before HSCT.
More precisely, lower relative abundance of Blautia was
associated with the subsequent aGvHD development,
confirming, in pediatric patients, previous observations
obtained in adults associating this symbiotic, acetate-produ-
cing genus with lower occurrence of aGvHD [8, 34]. Curi-
ously, a recent work based on a large number of Japanese
patients found no differences in Blautia abundance be-
tween aGvHD and non-aGvHD subjects [35]. However, as
stated by the authors themselves, the influence of lifestyle
Fig. 3 Gut microbiota variability at engraftment, in relation to aGvHD development. a PCoA based on Bray-Curtis distances of genus-level relative
abundance profiles of samples collected at the engraftment from patients who did not develop aGvHD (green), who developed aGvHD (I-II grade)
only involving the skin (gold), and who developed gastrointestinal aGvHD (II-IV grade) (dark red). Samples are identified by filled circles. First and
second principal components (MDS1 and MDS2) are plotted, accounting for 26.2 and 10.4% of variance in the dataset, respectively. The biplot of the
average bacterial coordinates weighted by the corresponding bacterial relative abundance per sample was superimposed on the PCoA plot for two of
the bacterial genera contributing to the ordination space (arrows). b Box and whiskers distribution of the relative abundance (%) of OTUs assigned to
the genus Bacteroides in samples collected before HSCT from subjects who did not develop aGvHD (green), who developed aGvHD (I-II grade) only
involving the skin (gold), and who developed gastrointestinal aGvHD (II-IV grade) (dark red). Log2 fold changes of the main discriminant genera
between pre-HSCT and engraftment samples in subjects who did not develop aGvHD (c), who developed aGvHD (I-II grade) only involving the skin
(d), and who developed gastrointestinal aGvHD (II-IV grade) (e). Genera for which P≤ 0.05 was obtained for at least one of the three groups of
subjects are shown (please see Additional file 2: Table S1) (O., Oscillospira; F., Faecalibacterium; [Ru.], [Ruminococcus]; Ro., Roseburia; L., Lachnospira;
D., Dorea; C., Coprococcus; Bl., Blautia; Bi., Bifidobacterium). Average values of log2 ratios are reported as bar plot, whereas dots identify the single values
obtained for each subject included in each group. Filled black dots and bacterial names in bold are used when the abundance of the OTUs assigned
to that genus was significantly different between pre-HSCT and engraftment samples (paired Wilcoxon test, P < 0.05), whereas empty circles are used
when the difference was not significant
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and nutrition on the GM composition might play a role in
determining the differences in GM response among popu-
lations. Indeed, the importance of relying on localized base-
lines in studies focused on GM and disease has recently
been stressed, [36] and Blautia has been identified as one
of the taxa most influenced by the degree of urbanization
[37].
On the contrary, higher pre-HSCT relative abun-
dances of Fusobacterium nucleatum were detected in
the subgroup of subjects who subsequently developed
aGvHD with gastrointestinal involvement. Fusobacter-
ium has never been linked to aGvHD occurrence in pre-
vious studies, but it has been reported to play an
etiological role in intestinal inflammation and colon can-
cer, [38–40] also in children, as in the case of pediatric
Crohn’s disease and appendicitis [41, 42]. The ability of
Fusobacterium to trigger the secretion of TNF-alpha and
IL-6 has been demonstrated by in vitro studies [43]. As
stated by Zeiser et al. [2] and Chen et al. [44], these cy-
tokines might recruit donor T cells responsible for
aGvHD complications. It is also worth mentioning that
the pre-HSCT GM of subjects who did not develop
aGvHD tended to show higher biodiversity and, coher-
ently, higher occurrence of several highly subdominant
bacterial groups, among which members of the Barne-
siellaceae family were reported. Interestingly, it was re-
cently hypothesized that the presence of Barnesiella in
the gut environment of HSCT patients might be protect-
ive against proliferation of vancomycin-resistant Entero-
coccus, one of the most important pathogens inducing
HSCT-related morbidity/mortality [6, 32, 45, 46].
The peculiarities of the pre-HSCT GM configuration
could, thus, contribute to the outcome of the immuno-
logical recovery following HSCT. In particular, the
higher ecosystem diversity, an increased relative abun-
dance of the symbiotic Blautia and lower relative abun-
dance of the known pathobiont F. nucleatum may
protect from severe aGvHD. These findings confirm the
importance of a healthy-like GM profile, i.e. a diverse
syntrophic ecosystem enriched in symbiotic species and
deprived of potentially pro-inflammatory members, to
face events that are microbiologically, immunologically
and metabolically challenging for the host, such as
HSCT and related procedures.
Interestingly, we found that the changes induced by
HSCT were less significant in subjects who developed
aGvHD with gastrointestinal involvement. An explan-
ation of this might reside in the low number of subjects
with gut aGvHD enrolled, but also in the greater
inter-individual variability in the GM composition
shown by these subjects with respect to non-aGvHD
and skin-only aGvHD subjects. It might be tempting to
hypothesize that the GM of subjects developing gut
aGvHD could have been already dysbiotic before HSCT,
with a strong individual variation. These observations
confirm previous findings on inflammatory bowel dis-
ease patients, whose GM was shown to fluctuate much
more than in healthy individuals, resulting in high
inter-patient variation [47]. This could be related to what
has been recently defined as the “Anna Karenina
principle”, stating that each dysbiotic microbial ecosys-
tem is dysbiotic in its own way [48]. Such a pattern
could have hindered commonalities in HSCT-related
variations.
At engraftment, patients with gut grade II-IV aGvHD
showed increasing Bacteroides relative abundance, indi-
cating a possible association between gut aGvHD and
early GM changes following HSCT. However, the num-
ber of children developing gut grade II-IV aGvHD was
low and unevenly distributed among hospitals: three at
the hospital of Verona, with gut aGvHD diagnosed be-
fore engraftment sampling took place, and three at the
hospital of Bologna, diagnosed after engraftment sam-
pling. No gut aGvHD samples were available from Rome
and Pavia hospitals. While this might have influenced
the results presented here, it highlights a possible role
that hospital-specific environmental bacteria might play
in favoring the onset and/or progression of aGvHD com-
plications. Indeed, OTUs assigned to the genus Erwinia,
and re-assigned to the known nosocomial species En-
terobacter cloacae, showed significantly higher levels in
samples taken at the Verona hospital than all the other
hospitals, and this feature was particularly evident in en-
graftment samples of patients developing gut aGvHD.
Finally, samples taken 30 days after HSCT did not
show significant differences in the gut ecosystem struc-
ture between children who either did or did not develop
aGvHD. We can, thus, suggest that early events in the
GM-host symbiosis are the ones that mostly impact on
donor-versus-host alloreactivity.
Conclusions
In the model we propose, the composition and diversity
of the GM, as it is before HSCT takes place, might lack
features of a healthy-like community, such as a sufficient
relative abundance of saccharolytic symbionts as Blau-
tia, or include risk factors for localized mucosal damage,
such as a higher presence of Fusobacterium nucleatum,
thus losing its resilience. Such GM might have more
chances, during pre-HSCT hospitalization and the
HSCT procedure, to evolve into a “pathobiome”, i.e. a
“health-care adapted pathogenic community”, [49] that
is unable to support immunological recovery in pediatric
patients. Even if the molecular mechanisms involved in
this process still need to be explored in further studies
by increasing the total number of cases, our data may
help support a rational approach to fecal material trans-
plantation in HSCT. Indeed, the association between
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GM configuration and gut aGvHD onset may help to
stratify pediatric patients according to the risk of devel-
oping gut aGvHD and, eventually, to rationally select the
best stool donor for a fecal material transplantation
approach able to provide the patient a beneficial,
aGvHD-protecting microbiota.
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